



## **COUNCIL FOR MEDICAL SCHEMES**

Private Bag X34, HATFIELD, 0028  
Hadefields Block E, 1267 Pretorius Street, HATFIELD

t: +27 (0)12 431-0500  
f: +27 (0)12 430-7644

<http://www.medicalschemes.com>

**Principal Officers  
Boards of Trustees  
Stakeholders**

t: +27 (0)12 431-0534

f: +27 (0)12 431-0634

Enquiries: [b.steenekamp@medicalschemes.com](mailto:b.steenekamp@medicalschemes.com)

Reference: REF entry and verification criteria

Date: Thursday, 28 August 2008

## **Circular 24 of 2008**

### **Invitation to comment on the guidelines for the identification of beneficiaries with REF risk factors in accordance with REF entry and verification criteria**

We are reviewing Version 3.2 of the guidelines of the Risk Equalisation Fund (REF) entry and verification criteria in preparation for Version 4 of these guidelines, which will be applicable to cases from 1 January 2009.

Please note that the Risk Equalisation Technical Advisory Panel (RETAP) has recommended that, subject to certain conditions, the DOT<sup>1</sup> (days of therapy) methodology be considered as an alternative to the current proof of treatment rules for schemes that apply bulk dispensing. The next version of the guidelines may incorporate this method.

Kindly submit written comments for consideration before Friday, 12 September 2007.

**Boshoff Steenekamp  
REF Project Specialist  
Council for Medical Schemes**

<sup>1</sup> **REF DOT Methodology**, 6 December 2007, available at  
[http://www.medicalschemes.com/publications/ZipPublications/RETAP%20Documents/REF\\_DOT.pdf](http://www.medicalschemes.com/publications/ZipPublications/RETAP%20Documents/REF_DOT.pdf)